MapLight (MPLT) GC Kristopher Hanson Receives RSU Award

What Happened
Kristopher Hanson, General Counsel of MapLight Therapeutics (MPLT), was granted equity awards on 2026-08-17: 7,730 shares (RSUs) reported as an award and 31,395 shares reported as a derivative award (total 39,125 RSUs). Each award was recorded at $0.00 per share (standard for RSU grants — no cash paid). These are compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: 2026-08-17; Form 4 filed 2026-08-19 (filed two days after the transaction, appearing to meet the SEC’s 2-business-day reporting window).
• Reported amounts/prices: 7,730 shares @ $0.00 (Award); 31,395 shares @ $0.00 (Derivative award). Total = 39,125 RSUs.
• Post-transaction ownership: Not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: These are restricted stock units (RSUs). Vesting: 1/4 of the RSUs vest on July 1, 2027, then 1/16th on each Oct 1, Jan 1, Apr 1 and July 1 thereafter, contingent on continued service.
  • F2: Each RSU represents the right to receive one share of voting common stock upon settlement.
  • F3: Describes an option vesting schedule but no option grant/exercise is reported in this filing.
• Transaction type: Award/Grant (code A) and derivative award — typically part of executive compensation, not an indicator of immediate buying or selling.

Context
RSUs are conditional awards that convert to company shares only after vesting and usually do not carry voting rights until settled. Because these awards were granted at $0, the immediate cash flow is zero for the insider; the economic value will depend on MapLight’s stock price at each vesting/settlement date. Grants like this are common as long-term compensation and should be viewed differently than open-market purchases (which may signal a direct personal investment).